Omeprazol Omezolan (Omeprazole)

Omeprazole, the active ingredient in Omezolan, is a proton pump inhibitor presented as a tablet for oral use. It reduces gastric acid secretion and is employed to manage conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, NSAID‑induced ulcer prophylaxis, and as part of Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Omezolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution.

Omeprazole is indicated for several acid‑related gastrointestinal disorders.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and esophageal irritation by maintaining a higher gastric pH. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence through sustained acid suppression. - NSA‑induced ulcer prophylaxis: reduces risk of gastric and duodenal ulcers in patients receiving non‑steroidal anti‑inflammatory drugs. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by creating a less acidic environment for bacterial clearance.

Omeprazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild, transient pain in the head. - Diarrhea: loose stools occurring during treatment. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort or cramping in the stomach area. - Flatulence: increased gas production.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat, or seizures. - Liver enzyme elevation: signs of hepatic injury detectable by blood tests. - Bone fracture risk: increased incidence of hip, wrist, or spine fractures with long‑term use.

When prescribing omeprazole, several safety considerations should be observed.

- Assess renal function: adjust use in patients with severe kidney impairment. - Evaluate need for long‑term therapy: limit duration to the shortest effective period. - Monitor for infections: be alert to signs of gastrointestinal or respiratory infections. - Review concomitant medications: consider potential interactions that may affect drug efficacy. - Avoid use in known hypersensitivity: discontinue if allergic reactions develop. - Store at room temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet activation, increasing cardiovascular risk. - Atazanavir, nelfinavir, rilpivirine: markedly decreased absorption, compromising antiviral efficacy. - Ketoconazole and itraconazole: impaired absorption leading to subtherapeutic antifungal levels.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: modest increase in serum levels, necessitating dose adjustment. - Methotrexate: elevated concentrations may enhance toxicity, especially at high doses. - Phenytoin: reduced plasma levels, potentially decreasing seizure control.